Cargando…

免疫抑制治疗后合并血流感染的重型再生障碍性贫血患者临床特征及预后分析

OBJECTIVE: To assess the clinical feature and outcomes of severe aplastic anemia (SAA) patients suffered from bacteremia following antithymocyte globulin (ATG). METHODS: A total of 264 cases hospitalized in our hospital between Jan 2000 and July 2011 were enrolled into this study. We evaluated the a...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342111/
https://www.ncbi.nlm.nih.gov/pubmed/27719726
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.09.015
_version_ 1783555368632188928
collection PubMed
description OBJECTIVE: To assess the clinical feature and outcomes of severe aplastic anemia (SAA) patients suffered from bacteremia following antithymocyte globulin (ATG). METHODS: A total of 264 cases hospitalized in our hospital between Jan 2000 and July 2011 were enrolled into this study. We evaluated the associated pathogens of bacteremia, analyzed the risk factors by Logistic regression and estimated the overall survival (OS) by Kaplan-Meier method for the cohort of patients. RESULTS: Bloodstream infections occurred in 49 patients, with a median age of 20 (4–62) years, including 38 cases with very SAA (VSAA) and 11 SAA patients. The median time of bacteremia was 13 (2–233) days following ATG administration. The most common microbiologically were Enterobacteriaceae (28.4%), Pseudomonas aeruginosa (20.9%) and Klebsiella pneumonia (14.9%). Almost half (46.9%) of these bacteria were resistant to most or all available antibacterial classes. Univariate and multivariate analyses demonstrated that VSAA, infections during previous week before ATG treatment were risk factors for bacteremia. The 3 and 6 months response rates (10.6% and 17.0%) were poor in the patients with bloodstream infections, which were significantly lower than those patients without infections (35.6% and 55.6%, respectively, both P<0.001). The estimated 5-year OS were 36.4% (95%CI 21.3% to 51.5%) and 74.5% (95%CI 68.4% to 80.7%) in the two groups, respectively (P<0.001). CONCLUSION: ①VSAA has higher risk of bacteremia than SAA; ②Infections during previous week before ATG administration was a risk factor for bacteremia; ③The outcomes of SAA or VSAA patients suffered from bacteremia following ATG was poor.
format Online
Article
Text
id pubmed-7342111
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73421112020-07-16 免疫抑制治疗后合并血流感染的重型再生障碍性贫血患者临床特征及预后分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To assess the clinical feature and outcomes of severe aplastic anemia (SAA) patients suffered from bacteremia following antithymocyte globulin (ATG). METHODS: A total of 264 cases hospitalized in our hospital between Jan 2000 and July 2011 were enrolled into this study. We evaluated the associated pathogens of bacteremia, analyzed the risk factors by Logistic regression and estimated the overall survival (OS) by Kaplan-Meier method for the cohort of patients. RESULTS: Bloodstream infections occurred in 49 patients, with a median age of 20 (4–62) years, including 38 cases with very SAA (VSAA) and 11 SAA patients. The median time of bacteremia was 13 (2–233) days following ATG administration. The most common microbiologically were Enterobacteriaceae (28.4%), Pseudomonas aeruginosa (20.9%) and Klebsiella pneumonia (14.9%). Almost half (46.9%) of these bacteria were resistant to most or all available antibacterial classes. Univariate and multivariate analyses demonstrated that VSAA, infections during previous week before ATG treatment were risk factors for bacteremia. The 3 and 6 months response rates (10.6% and 17.0%) were poor in the patients with bloodstream infections, which were significantly lower than those patients without infections (35.6% and 55.6%, respectively, both P<0.001). The estimated 5-year OS were 36.4% (95%CI 21.3% to 51.5%) and 74.5% (95%CI 68.4% to 80.7%) in the two groups, respectively (P<0.001). CONCLUSION: ①VSAA has higher risk of bacteremia than SAA; ②Infections during previous week before ATG administration was a risk factor for bacteremia; ③The outcomes of SAA or VSAA patients suffered from bacteremia following ATG was poor. Editorial office of Chinese Journal of Hematology 2016-09 /pmc/articles/PMC7342111/ /pubmed/27719726 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.09.015 Text en 2016年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
免疫抑制治疗后合并血流感染的重型再生障碍性贫血患者临床特征及预后分析
title 免疫抑制治疗后合并血流感染的重型再生障碍性贫血患者临床特征及预后分析
title_full 免疫抑制治疗后合并血流感染的重型再生障碍性贫血患者临床特征及预后分析
title_fullStr 免疫抑制治疗后合并血流感染的重型再生障碍性贫血患者临床特征及预后分析
title_full_unstemmed 免疫抑制治疗后合并血流感染的重型再生障碍性贫血患者临床特征及预后分析
title_short 免疫抑制治疗后合并血流感染的重型再生障碍性贫血患者临床特征及预后分析
title_sort 免疫抑制治疗后合并血流感染的重型再生障碍性贫血患者临床特征及预后分析
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342111/
https://www.ncbi.nlm.nih.gov/pubmed/27719726
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.09.015
work_keys_str_mv AT miǎnyìyìzhìzhìliáohòuhébìngxuèliúgǎnrǎndezhòngxíngzàishēngzhàngàixìngpínxuèhuànzhělínchuángtèzhēngjíyùhòufēnxī
AT miǎnyìyìzhìzhìliáohòuhébìngxuèliúgǎnrǎndezhòngxíngzàishēngzhàngàixìngpínxuèhuànzhělínchuángtèzhēngjíyùhòufēnxī
AT miǎnyìyìzhìzhìliáohòuhébìngxuèliúgǎnrǎndezhòngxíngzàishēngzhàngàixìngpínxuèhuànzhělínchuángtèzhēngjíyùhòufēnxī
AT miǎnyìyìzhìzhìliáohòuhébìngxuèliúgǎnrǎndezhòngxíngzàishēngzhàngàixìngpínxuèhuànzhělínchuángtèzhēngjíyùhòufēnxī
AT miǎnyìyìzhìzhìliáohòuhébìngxuèliúgǎnrǎndezhòngxíngzàishēngzhàngàixìngpínxuèhuànzhělínchuángtèzhēngjíyùhòufēnxī
AT miǎnyìyìzhìzhìliáohòuhébìngxuèliúgǎnrǎndezhòngxíngzàishēngzhàngàixìngpínxuèhuànzhělínchuángtèzhēngjíyùhòufēnxī
AT miǎnyìyìzhìzhìliáohòuhébìngxuèliúgǎnrǎndezhòngxíngzàishēngzhàngàixìngpínxuèhuànzhělínchuángtèzhēngjíyùhòufēnxī
AT miǎnyìyìzhìzhìliáohòuhébìngxuèliúgǎnrǎndezhòngxíngzàishēngzhàngàixìngpínxuèhuànzhělínchuángtèzhēngjíyùhòufēnxī
AT miǎnyìyìzhìzhìliáohòuhébìngxuèliúgǎnrǎndezhòngxíngzàishēngzhàngàixìngpínxuèhuànzhělínchuángtèzhēngjíyùhòufēnxī
AT miǎnyìyìzhìzhìliáohòuhébìngxuèliúgǎnrǎndezhòngxíngzàishēngzhàngàixìngpínxuèhuànzhělínchuángtèzhēngjíyùhòufēnxī